Schrödinger, Inc. (SDGR)
| Market Cap | 1.53B +6.5% |
| Revenue (ttm) | 259.04M +8.9% |
| Net Income | -54.34M |
| EPS | -0.74 |
| Shares Out | 74.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,043 |
| Open | 19.25 |
| Previous Close | 19.50 |
| Day's Range | 19.24 - 20.53 |
| 52-Week Range | 10.95 - 23.02 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 21.43 (+4.79%) |
| Earnings Date | Aug 5, 2026 |
About SDGR
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and cli... [Read more]
Financial Performance
In 2025, Schrödinger's revenue was $255.87 million, an increase of 23.29% compared to the previous year's $207.54 million. Losses were -$103.27 million, -44.81% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price target is $21.43, which is an increase of 4.79% from the latest price.
News
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live...
Schrodinger assumed with a Neutral at UBS
UBS assumed coverage of Schrodinger (SDGR) with a Neutral rating with a price target of $19, up from $13. The company’s software growth outlook appears broadly aligned with market expectations,…
Schrodinger reports inducement grants under Nasdaq listing rule
Schrodinger (SDGR) reported that on August 12, 2026, the company granted restricted stock units with respect to 3,315 shares of the company’s common stock to two newly hired employees. These…
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's comm...
Schrodinger raises FY26 drug discovery revenue view $65M-$75M from $55M-$65M
As of August 5, 2026, Schrodinger (SDGR) provided the following financial guidance for the fiscal year ending December 31, 2026: ACV is expected to range from $21M-$228M, representing 10-15% growth…
Schrödinger Earnings Call Transcript: Q2 2026
Q2 2026 saw 27% ACV growth, strong software and drug discovery performance, and the launch of Bunsen, the AI co-scientist. Hosted software adoption accelerated, operating expenses declined, and net income turned positive. Full-year guidance was raised on robust demand and new collaborations.
Schrödinger Earnings release: Q2 2026
Schrödinger released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Schrödinger Quarterly report: Q2 2026
Schrödinger has published its Q2 2026 quarterly earnings report on August 5, 2026.
Schrödinger Slides: Q2 2026
Schrödinger has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Schrödinger Reports Second Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Today Schrödinger announced financial results for the quarter ended June 30, 2026.
Schrodinger announces collaboration, software agreement with Bristol Myers
Schrodinger (SDGR) announced a strategic agreement with Bristol Myers Squibb (BMY) to deploy Bunsen, Schrodinger’s agentic AI co-scientist, within its research organization. The new agreement signific...
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.
Schrodinger introduces Bunsen AI co-scientist for molecular discovery
Schrodinger (SDGR) announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational strategies...
Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
NEW YORK--(BUSINESS WIRE)---- $SDGR #BunsenAI--Schrödinger, Inc. today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist.
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host...
Schrodinger reports inducement grants under Nasdaq listing rule
Schrodinger (SDGR) reported that on July 16, the company granted restricted stock units with respect to 3,691 shares of the company’s common stock to four newly hired employees. These grants…
Schrödinger Transcript: AGM 2026
The meeting confirmed a quorum, approved all proposals including director elections, executive compensation, and an equity plan amendment, and ratified the auditor. Strategic updates highlighted the company's AI-driven molecular discovery platform and its strong track record.
Schrodinger reports inducement grants under Nasdaq listing rule
Schrodinger (SDGR) reported that on June 12, 2026, the company granted restricted stock units with respect to 10,771 shares of the company’s common stock to seven newly hired employees. These…
Schrödinger Transcript: RBC Capital Markets Global Healthcare Conference 2026
Biotech and pharma funding environments have improved, driving new customer growth and increased technology adoption. Early-stage computational tools and AI are accelerating drug discovery, with new products like Bunsen and predictive toxicology expected to boost license consumption and reduce late-stage failures.
Schrodinger price target lowered to $17 from $19 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Schrodinger (SDGR) to $17 from $19 and keeps an Equal Weight rating on the shares.
Schrödinger Transcript: Bank of America Global Healthcare Conference 2026
Q1 results exceeded guidance with broad-based growth, strong hosted revenue adoption, and disciplined expense management. Product innovation continues with predictive toxicology, LiveDesign Biologics, and Bunsen AI, while the transition to hosted solutions is on track. Nearly 100% customer retention and a robust track record support a positive outlook.
Schrödinger Earnings Call Transcript: Q1 2026
Q1 2026 saw 12% ACV growth and strong drug discovery revenue, with hosted software adoption accelerating and a major liquidity event from the Ajax Therapeutics acquisition. Guidance for 2026 remains robust, with continued investment in technology and a strong cash position.
Schrödinger Earnings release: Q1 2026
Schrödinger released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Schrödinger Quarterly report: Q1 2026
Schrödinger has published its Q1 2026 quarterly earnings report on May 5, 2026.
Schrödinger Slides: Q1 2026
Schrödinger has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.